Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
Date:2/11/2009

(A Development Stage Enterprise) CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Three Months Ended Year Ended Dec. 31, Dec. 31, Dec. 31, Dec. 31, 2008 2007 2008 2007 Revenues from services $- $- $- $- Operating expenses: Research and development 3,559,543 12,574,735 23,935,541 47,234,867 General and administrative 4,095,118 9,472,938 28,909,580 32,803,508 Total operating expenses 7,654,661 22,047,673 52,845,121 80,038,375 Loss from operations (7,654,661) (22,047,673) (52,845,121) (80,038,375) Interest income 150,642 1,299,076 1,780,880 5,907,219 Other income - - - 71,345 Total other income, net 150,642 1,299,076 1,780,880 5,978,564 Loss before tax provision (7,504,019) (20,748,597) (51,064,241) (74,059,811) Tax provision - (191) - 9,879 Net loss $(7,504,019) $(20,748,406) $(51,064,241) $(74,069,690) Basic and diluted net loss per share attributable to common stockholders $(0.28) $(0.78) $(1.92) $(2.81) Shares used in calculation of basic and diluted net loss per share attributable to common stockholders 26,652,187 26,644,540 26,650,126 26,360,177 VANDA PHARMACEUTICALS INC. (A Development Stage Enterprise) CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) December 31, December 31,
'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
2. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
3. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
4. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
5. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
6. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
8. Sagent Pharmaceuticals Announces Expansion of Cefazolin Product Line to Include Cefazolin for Injection, USP in 500mg Single-Dose Vial
9. PacificGMP and LigoCyte Pharmaceuticals Announce cGMP Manufacturing Collaboration
10. Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida
11. Tigris Pharmaceuticals Files IND Application for GGTI-2418
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014) – The severe flooding that devastated a wide ... destructive if the bridges, roads and other infrastructure had ... from the University of Colorado Denver. , "People need ... Jimmy Kim, PhD, associate professor of structural engineering at ... and lead author the study. "There is an assumption ...
(Date:10/27/2014)... WORCESTER, Mass. and TORONTO ... Biotechnology Corporation ( www.generex.com ) (OTCQB: GNBT) today ... the immunological response triggered by its novel proprietary ... of relapse in breast cancer patients. The AE37 ... wholly-owned subsidiary, Antigen Express, Inc. ( www.antigenexpress.com ). ...
(Date:10/27/2014)... Florida (PRWEB) October 27, 2014 ... at reducing and eliminating several types of pediatric ... not been achieved in over 30 years of ... Noah's Light Foundation, proves that one mom's determination ... diagnosed just before Halloween trick-or-treating, and it’s only ...
(Date:10/27/2014)... , October 27, 2014 Investor-Edge ... Inc. (NASDAQ: NBIX ), Insmed Inc. (NASDAQ: ... BCRX ), Dyax Corporation (NASDAQ: DYAX ... these five companies can be accessed at: http://investor-edge.com/register ... NASDAQ Composite ended at 4,483.72, up 0.69%, the Dow ...
Breaking Biology Technology:CU Denver study says upgrading infrastructure could reduce flood damage 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5
... As the Office of Naval Research (ONR) increases its ... number of hurdles need to be overcome including autonomy ... an Aug. 18 conference on unmanned systems. "We ... for the Navy and Marine Corps," said Dr. Larry ...
... developed new nano-structured glass, turning it into new type ... and will significantly reduce the cost of medical imaging. ... converter created by femtosecond laser nanostructuring of glass published ... by Professor Peter Kazansky at the University,s Optoelectronics Research ...
... Aug. 18, 2011 CBI is pleased to announce ... and Post-Approval Studies Congress, being held September 20-22, 2011 ... an impressive speaker lineup from Celgene, Covidien, FDA, Forest, ... more. Attendees have the opportunity to ...
Cached Biology Technology:Office of Naval Research taking on challenges of unmanned underwater vehicles 2New nanostructured glass for imaging and recording 2FDA, NIH to Speak at CBI's 14th Annual Registries and Post-Approval Studies Congress 2
(Date:10/28/2014)... tragic realities of cancer is that the drugs ... their effectiveness varies unpredictably from patient to patient. ... change this reality by rapidly assessing how effective ... cancer before chemotherapy begins. , A team of ... Professor Melissa Skala has developed the technique, which ...
(Date:10/28/2014)... Researchers from the National University of Singapore (NUS) have ... - breeding and laying direct developing eggs in live ... the white spotted bush frog ( Raorchestes chalazodes ... of two species known to adopt this novel reproductive ... of London,s Biological Journal of the Linnean Society ...
(Date:10/27/2014)... University researchers have delivered a scientific one-two punch with ... fibers self-assemble via their sticky ends. , Collagen is ... of bone and the fibrous tissues that support cells ... to better synthetic collagen for tissue engineering and cosmetic ... Hartgerink has been studying synthetic collagen for a decade, ...
Breaking Biology News(10 mins):Improving breast cancer chemo by testing patient's tumors in a dish 2Improving breast cancer chemo by testing patient's tumors in a dish 3NUS researchers discover for the first time that a rare bush frog breeds in bamboo 2NUS researchers discover for the first time that a rare bush frog breeds in bamboo 3'Sticky' ends start synthetic collagen growth 2'Sticky' ends start synthetic collagen growth 3
... team of French and German researchers report in the ... http://www.fasebj.org ) that people with limb-girdle muscular dystrophy are ... to prevent the loss of muscle tissue. By targeting ... protein, scientists could develop new drugs to stop muscle ...
... thing could be harmful to the environment. For years, ... bacteria and, recently, have used this knowledge to create ... Missouri researcher has found that silver nanoparticles also may ... from wastewater treatment systems. The study was funded by ...
... and Canadian scientists expect to begin trials next month (May) ... of energy trapped in the world,s unrecoverable heavy oil deposits. ... because the oil has become either solid or too thick ... conventional means. , However, scientists at Newcastle University, England, and ...
Cached Biology News:Researchers discover molecular basis of a form of muscular dystrophy 2Too much technology may be killing beneficial bacteria 2Scientists aim to boost world energy supplies -- with microbes! 2Scientists aim to boost world energy supplies -- with microbes! 3Scientists aim to boost world energy supplies -- with microbes! 4